Trevi Therapeutics (TRVI) Set to Post Quarterly Earnings on Monday

Key Points

• Trevi Therapeutics is scheduled to report Q3 2026 results after the market closes Monday, November 9; analysts expect a loss of about $0.13 per share. Its prior-quarter loss of $0.11 per share matched consensus.
• Shares recently traded at $13.63, down 1.7% on the day. Analysts’ consensus is “Moderate Buy,” with a $27.08 price target.
• Director Michael Heffernan sold 39,473 shares, reducing his holdings by 86.14%; company insiders collectively own 15.39% of shares.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) is expected to release its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to announce earnings of ($0.1317) per share for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, hitting analysts' consensus estimates of ($0.11). On average, analysts expect Trevi Therapeutics to post ($0.48) EPS for the current fiscal year and ($0.62) EPS for the next fiscal year.

Trevi Therapeutics Stock Down 1.7%

TRVI traded down $0.23 during trading on Wednesday, reaching $13.63. 223,275 shares of the stock traded hands, compared to its average volume of 1,792,198. The stock's 50-day moving average is $14.52 and its 200 day moving average is $14.34. Trevi Therapeutics has a 12 month low of $9.82 and a 12 month high of $20.22. The stock has a market capitalization of $1.94 billion, a PE ratio of -40.07 and a beta of 1.15.

Insiders Place Their Bets

In other news, Director Michael Heffernan sold 39,473 shares of the company's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $15.09, for a total transaction of $595,647.57. Following the transaction, the director owned 6,351 shares in the company, valued at approximately $95,836.59. This represents a 86.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 15.39% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Raymond James Financial reissued a "strong-buy" rating and issued a $40.00 price objective on shares of Trevi Therapeutics in a research note on Friday, August 7th. BMO Capital Markets reaffirmed an "outperform" rating on shares of Trevi Therapeutics in a research note on Wednesday, October 7th. Wall Street Zen downgraded Trevi Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, July 25th. Cantor Fitzgerald boosted their price target on Trevi Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Finally, B. Riley Financial increased their price target on Trevi Therapeutics from $21.00 to $31.00 and gave the stock a "buy" rating in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Trevi Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.08.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for chronic conditions that have limited therapeutic options. The company's lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine, an opioid receptor modulator designed to combine kappa-opioid receptor agonism with mu-opioid receptor antagonism.

Trevi is evaluating Haduvio in conditions involving chronic cough and severe itching. Its clinical development programs have included studies in chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, and chronic pruritus associated with systemic sclerosis, an autoimmune connective-tissue disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.